Addition of irinotecan to CTRT as preoperative treatment for locally advanced rectal cancer (ARISTOTLE Trial) DOI: 10.1016/S1470-2045(26)00132-4⁠ 75 UK centres=564 pts MRI-defined high-risk rectal cancers Adding concurrent irinotecan did not improve DFS, but added Toxicity

Antibody–drug conjugates in breast cancer — first-line and curative settings Current Opinion in Oncology. 2026;38:441–448. DOI:10.1097/CCO.0000000000001265

PD-1/PD-L1 inhibitors combined with SRS for brain metastases: Critical appraisal Systematic review and meta-analysis · Published 17 October 2026 · Volume 43, Article 58 34 studies (2016-2025) 2587 Brain mets Hypothesis and Feasibility testing Not for Clinics yet

Decoding Hereditary Breast & ovarian Cancer Conglomerates all evidence over last 5 years High intensity summary Identify patients Estimate incidences Decide Testing Managing = Risk Reducing Sx Vs Chemoprevention Vs Surveillance

Path CR and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. DOI: 10.1016/S0140-6736(13)62422-8 Does achieving a pCR after neoadjuvant systemic therapy reliably predict improved long-term survival? 12 trials,11955 pts @5.4y IPD Answer = No It does nt

Adverse effects of immune-checkpoint inhibitors Nature Reviews Clinical Oncology. 2019;16:563–580. DOI: 10.1038/s41571-019-0218-0. Early recognition, prompt treatment and multidisciplinary management are essential to reducing severe toxicity and treatment-related deaths.

Ozonated water mouthrinse for radiation-induced oral mucositis DOI: 10.1007/s00520-026-11343-0. N=65 NPc pts undergoing RT Primary endpoint =Time to first WHO grade ≥2 oral mucositis The observed reduction in mucositis—from 90 to 50% at 30#—is striking and clinically relevant

5y toxicity after ultra-hypofractionated WBRT with SIB doi.org/10.1016/j.ijrobp.202… N=242 Median FU 64m 26 Gy/5# with a SIB of 29 Gy/5# was associated with low rates of most recorded late toxicities @5y. However, persistent breast pain was more frequent in pts who received the boost

Comparative dosing of bevacizumab for radiation necrosis: impact of tumor type on edema response⁠ Study compares 7.5 mg/kg Vs 10 mg/kg q3w. Its principal message is not that the lower dose is definitively superior, but that radiographic outcomes were broadly similar

SPECT-guided active bone marrow-sparing radiotherapy (ABMS-VMAT), + with prophylactic pegylated G-CSF, can reduce severe neutropenia during platinum-doublet CTRT for locally advanced cervical cancer. Phase II Trial 54 pts with FIGO 2018 stage IIA2–IVA cervical cancer

Neoadjuvant SABR before IVC thrombectomy in renal cell carcinoma Ph II Patients received either 40 Gy/5# or 36 Gy /3 #, followed by surgery 4–14 d later. N=21 included in the primary efficacy analysis 1-year RFS was 71.4%, compared with a historical surgery-alone = 55.7%.

Survival after lymph node dissection, radiotherapy, and combined treatment in sentinel node–positive stage IIIA Merkel cell carcinoma: A systematic review and meta-analysis. JAAD International, 2026;29:28–40 · DOI: 10.1016/j.jdin.2026.06.025 8 studies = 1825 pts

Lunar Trial Ph II 177Lu-PSMA Prior to SBRT in Oligorecurrent Prostate Cancer: DOI: 10.1016/j.eururo.2026.09.005 N=92 1–5 PSMA PET/CT-detected lesions amenable to SBRT 45pts = 2# Lu, 6.8 GBq per cycle then SBRT after 8w 42 = Upfront SBRT Median PFS +10.2 m benefit

Relapsed/refractory GCT, alongside the EBMT guidance on managing poor stem-cell mobilisers GCSF plus plerixafor rescue remobilisation regimen Regimen A — G-CSF + plerixafor remobilisation Regimen B — Chemotherapy mobilisation followed by G-CSF + plerixafor

Do all.women above Age 60 need Breast boost after BCS especially.if HR + EBC

Newly diagnosed, transplant-ineligible multiple myeloma, or for relapsed/refractory disease Daratumumab + Lenalidomide + Dexamethasone Detail Protocol